2-(2,5-二甲基苯氧基)丙酸乙酯 | 153472-90-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-(2,5-二甲基苯氧基)丙酸乙酯
• 英文名称: ethyl 2-(2,5-dimethylphenyl)oxypropionate
• 英文别名: 2-(2,5-dimethyl-phenoxy)-propionic acid ethyl ester；2-(2,5-Dimethyl-phenoxy)-propionsaeure-aethylester；Propanoic acid, 2-(2,5-dimethylphenoxy)-, ethyl ester；ethyl 2-(2,5-dimethylphenoxy)propanoate
• CAS: 153472-90-3
• 化学式: C₁₃H₁₈O₃
• 分子量: 222.284
• InChiKey: KKBMTACYQCWETE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  16
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-(2,5-二甲基苯氧基)丙酸乙酯 在 氯化亚砜 、 三乙胺 作用下， 以 乙醚 、 二氯甲烷 为溶剂， 反应 0.5h， 生成 2-methyl-3-(2,5-dimethylphenyl)oxy-1-butene
  参考文献：
  名称：

  Facile Syntheses of 2-Alkyl-2,3-dihydro-2-methylbenzofuran Derivatives

  摘要：

  Various 2-alkyl-2,3-dihydro-2-methylbenzofurans 4 can be easily synthesized from 2-aryloxypropionic acid ethyl esters 1 by 3 steps in good yields.

  DOI：

  10.1080/00397919408010194
• 作为产物：
  描述：

  2,5-二甲基苯酚 、 2-溴丙酸乙酯 在 potassium iodide 作用下， 以 N,N-二甲基甲酰胺 、 丙酮 为溶剂， 以80%的产率得到2-(2,5-二甲基苯氧基)丙酸乙酯
  参考文献：
  名称：

  Facile Syntheses of 2-Alkyl-2,3-dihydro-2-methylbenzofuran Derivatives

  摘要：

  Various 2-alkyl-2,3-dihydro-2-methylbenzofurans 4 can be easily synthesized from 2-aryloxypropionic acid ethyl esters 1 by 3 steps in good yields.

  DOI：

  10.1080/00397919408010194

文献信息

• Novel carnitine conjugates as dual prodrugs and uses thereof
  申请人：Goel P. Om

  公开号：US20050101572A1

  公开（公告）日：2005-05-12

  The present invention discloses novel dual prodrug compositions of Formula 1, wherein A is a single bond, —O—, or —CH 2 —; m and n vary from 0 to 15; p and q vary from 0 to 4; B is a single bond or —CR 3 R 4 ; D is selected from the group consisting —CO 2 R 5 , —OR 6 , —OCOR 7 , —SO 3 R 8 , —SO 2 NH 2 , —OPO(OR 9 )(OR 10 ), —OPO(OR 9 )(NH 2 ), —OPO(OR 9 )—O—PO(OR 10 )(OR 11 ), R 1 to R 11 are various substituents selected to optimize the physicochemical and biological properties such as, lipophilicity, toxicity, bioavailability, and pharmacokinetics of compounds of Formula 1. These compounds are useful for the treatment of various cardiovascular and neurological disorders.

  本发明揭示了一种新型的Formula 1的双前药组合物，其中A是一个单键，-O-或-CH2-；m和n的取值范围为0至15；p和q的取值范围为0至4；B是一个单键或-CR3R4；D从以下组合中选择：-CO2R5，-OR6，-OCOR7，-SO3R8，-SO2NH2，-OPO(OR9)(OR10)，-OPO(OR9)(NH2)，-OPO(OR9)-O-PO(OR10)(OR11)，R1至R11是各种取代基，用于优化Formula 1化合物的理化和生物性质，如脂溶性、毒性、生物利用度和药代动力学。这些化合物可用于治疗各种心血管和神经系统疾病。
• CCL5 inhibitors
  申请人：AFECTA PHARMACEUTICALS, INC.

  公开号：US10940132B2

  公开（公告）日：2021-03-09

  Compounds, pharmaceutically acceptable salts, esters, prodrugs, and pharmaceutical compositions thereof are disclosed that are useful for inhibition of the biological activity of CCL5 on mammalian cells, as well as methods of treatment for diseases involving the increased biological activity of CCL5.

  所公开的化合物、药学上可接受的盐、酯、原药及其药物组合物有助于抑制 CCL5 在哺乳动物细胞上的生物活性，以及治疗涉及 CCL5 生物活性增加的疾病的方法。
• Azzolina; Collina; Ghislandi, Il Farmaco, 1993, vol. 48, # 10, p. 1401 - 1416
  作者：Azzolina、Collina、Ghislandi

  DOI：——

  日期：——
• Bischoff, Chemische Berichte, 1900, vol. 33, p. 1254
  作者：Bischoff

  DOI：——

  日期：——
• Methods of treating various diseases using carnitine conjugates as dual prodrugs
  申请人：Goel Om P.

  公开号：US20080188444A1

  公开（公告）日：2008-08-07

  The present invention discloses uses for treating various diseases with novel dual prodrug compounds of Formula 1, wherein A is selected from the group consisting of a single bond, —O—, or —CH 2 —; m and n vary independently and are an integer from 1 to 15; p and q vary independently from 0 to 1; B is —CR 3 R 4 ; D is selected from the group consisting of —CO 2 R 5 , —OR 6 , —OCOR 7 , —SO 3 R 8 , —SO 2 NH 2 , —OPO(OR 9 )(OR 10 ), —OPO(OR 9 )(NH 2 ), —OPO(OR 9 )—O—PO(OR 10 )(OR 11 ), wherein R 1 to R 4 are independently selected from C 1 -C 6 alkyl; and R 5 to R 11 are independently selected from the group consisting of hydrogen; C 1 -C 6 alkyl; C 3 -C 6 cycloalkyl; C 2 -C 6 alkenyl; C 6 alkynyl; C 5 -C 10 aryl unsubstituted or substituted with C 1 -C 6 alkyl, hydroxyl, C 1 -C 6 alkoxyl, 1,3-dioxolanyl, cyano, halo, nitro, trihaloalkyl, carboxyl, C 1 -C 6 acyl, C 1 -C 6 hydroxyalkyl, amino, C 1 -C 6 alkylamino, C 1 -C 6 dialkylamino, C 1 -C 6 acylamino, C 1 -C 6 alkoxylcarbonyl; C 5 -C 6 arylalkyl unsubstituted or substituted with C 1 -C 6 alkyl, hydroxyl, C 1 -C 6 alkoxyl, 1,3-dioxolanyl, cyano, halo, trihaloalkyl, carboxyl, C 1 -C 6 acyl, C 1 -C 6 hydroxyalkyl, amino, C 1 -C 6 alkylamino, C 1 -C 6 dialkylamino, C 1 -C 6 alkoxylcarbonyl; C 1 -C 6 carboxyalkyl; C 1 -C 6 acylamino; C 1 -C 6 sulfonatoalkyl; C 1 -C 6 sulfamylalkyl; and C 1 -C 6 phosphonatoalkyl. The various terms in Formula 1 are selected to optimize the physiochemical and biological properties such as, lipophilicity, bioavailability, and pharmacokinetics of compounds of Formula 1. There compounds are useful for the treatment of various metabolic, cardiovascular and neurological disorders.